Results 201 to 210 of about 34,140,631 (244)

Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes. [PDF]

J Virol
Zhou R, Yue M, Shen Q, Liu N, Chen Y, Wang P, Kim K, Yang R, Chen H, Yuen K-Y, To KK-W, Xu A, Chen Z.   +12 more
europepmc   +1 more source

Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes. [PDF]

J Diabetes Investig
Yu YT, Lee YC, Fang YW, Hsieh WH, Tsai MH.   +4 more
europepmc   +1 more source

Liraglutide and Βeta‐Cell Function in Young Adults With Long‐Standing Type 1 Diabetes and Residual C‐Peptide: A Blinded, Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effect of liraglutide on residual beta‐cell function in adults with long‐standing type 1 diabetes (T1D) and detectable C‐peptide. Materials and Methods In this randomized, blinded, placebo‐controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C‐peptide were assigned to liraglutide or placebo for 52 
José Caballero‐Corbalán, Per Lundkvist, Daniel Espes, Per‐Ola Carlsson   +3 more
wiley   +1 more source

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus? [PDF]

Cureus
Medeiros R, Mendes I.
europepmc   +1 more source

Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González, Alejandro Matamoros‐Domínguez, Juan Manuel Espinosa‐Cabello, Gisela Pérez‐Muñoz, Manuel Jesús León Aranda, María Del Carmen Roque‐Cuellar, Silvia García‐Rey, Andrés Jiménez‐Sánchez, Antonio Jesús Martínez‐Ortega, Miguel Ángel Mangas‐Cruz, Isabel Cerrillo, Javier S. Perona, Pedro Pablo García‐Luna, Elena María Yubero‐Serrano, José María Castellano   +14 more
wiley   +1 more source

Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data. [PDF]

Mayo Clin Proc Digit Health
Chabassier A, Vittrant B, Binon P, Scornet E, Josse J.   +4 more
europepmc   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention. [PDF]

J Cosmet Dermatol
Kruglikov IL.
europepmc   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. [PDF]

Arthritis Rheumatol
Haberman RH, Rice AL, Chen K, Scher U, Thib S, Scher JU, Eder L.   +6 more
europepmc   +1 more source